H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) dropped 49.5% during trading on Wednesday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Down 49.5 %
The firm’s 50 day moving average price is $2.02 and its two-hundred day moving average price is $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 2 Drone Stocks Surging from Increased Media Attention
- When to Sell a Stock for Profit or Loss
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
